2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03707795 (ClinicalTrials.gov) | August 21, 2017 | 14/9/2017 | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Familial Amyotrophic Lateral Sclerosis | Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | Edward Kasaraskis | NULL | Completed | 20 Years | 80 Years | All | 6 | Early Phase 1 | United States |
| 2 | EUCTR2006-001688-49-GB (EUCTR) | 14/08/2006 | 28/04/2006 | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | Early stage of amyotrophic lateral sclerosis (ALS) MedDRA version: 8.1;Level: PT;Classification code 10002026 | Product Name: 40 mg glatiramer acetate Product Code: 40 mg GA | TEVA Pharmaceutical Industries. Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 366 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Belgium;Germany;Italy;United Kingdom | ||
| 3 | EUCTR2006-001688-49-DE (EUCTR) | 31/07/2006 | 24/05/2006 | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | Early stage of amyotrophic lateral sclerosis (ALS) MedDRA version: 8.1;Level: PT;Classification code 10002026 | Product Name: 40 mg glatiramer acetate Product Code: 40 mg GA | TEVA Pharmaceutical Industries. Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 300 | United Kingdom;Germany;Belgium;Italy | |||
| 4 | EUCTR2006-001688-49-BE (EUCTR) | 26/06/2006 | 10/05/2006 | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. | Early stage of amyotrophic lateral sclerosis (ALS) MedDRA version: 8.1;Level: PT;Classification code 10002026 | Product Name: 40 mg glatiramer acetate Product Code: 40 mg GA | TEVA Pharmaceutical Industries. Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Germany;United Kingdom;Belgium;Italy |